Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147,179,178
-
Total 13F shares
-
135,496,675
-
Share change
-
-2,221,399
-
Total reported value
-
$1,967,413,218
-
Put/Call ratio
-
53%
-
Price per share
-
$14.52
-
Number of holders
-
236
-
Value change
-
-$29,612,796
-
Number of buys
-
122
-
Number of sells
-
90
Institutional Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q3 2025
As of 30 Sep 2025,
Denali Therapeutics Inc. - COMMON STOCK (DNLI) was held by
236 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
135,496,675 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, BAILLIE GIFFORD & CO, FMR LLC, T. Rowe Price Investment Management, Inc., UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC, STATE STREET CORP, Temasek Holdings (Private) Ltd, Capital Research Global Investors, and PRICE T ROWE ASSOCIATES INC /MD/.
This page lists
236
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.